Pages that link to "Q42482163"
Jump to navigation
Jump to search
The following pages link to GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide (Q42482163):
Displaying 50 items.
- The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity (Q26765609) (← links)
- Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (Q26778608) (← links)
- Adverse Effects of GLP-1 Receptor Agonists (Q26801346) (← links)
- Lixisenatide as add-on therapy to basal insulin (Q27007547) (← links)
- Action and therapeutic potential of oxyntomodulin (Q27025870) (← links)
- Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association (Q28076059) (← links)
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program (Q31066859) (← links)
- Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas (Q33603384) (← links)
- Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases (Q33944105) (← links)
- Incretin-based therapies in prediabetes: Current evidence and future perspectives (Q34699191) (← links)
- The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. (Q35022184) (← links)
- Emerging role of insulin with incretin therapies for management of type 2 diabetes (Q35214425) (← links)
- LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. (Q35508894) (← links)
- Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. (Q35654002) (← links)
- GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. (Q35762689) (← links)
- Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials (Q35780935) (← links)
- A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer (Q36011482) (← links)
- Glucagon like peptide-1 receptor expression in the human thyroid gland (Q36141532) (← links)
- Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial) (Q36220895) (← links)
- Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial (Q36249636) (← links)
- Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? (Q36410243) (← links)
- Gut hormones: the future of obesity treatment? (Q36468102) (← links)
- Cardiovascular biology of the incretin system (Q36484283) (← links)
- Clinical comments related to medullary thyroid cancer diagnosis and management. (Q36690566) (← links)
- Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER (Q36800401) (← links)
- Interpreting adverse signals in diabetes drug development programs (Q36942266) (← links)
- A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology (Q37019943) (← links)
- Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls (Q37193295) (← links)
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study (Q37225065) (← links)
- The vitamin d receptor in thyroid development and function (Q37290899) (← links)
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial (Q37320537) (← links)
- Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy (Q37402786) (← links)
- Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum (Q37517909) (← links)
- Do GLP-1-based therapies increase cancer risk? (Q37577143) (← links)
- Comparative effectiveness of liraglutide in the treatment of type 2 diabetes (Q37659673) (← links)
- Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus (Q37941683) (← links)
- Liraglutide: a review of its use in the management of type 2 diabetes mellitus (Q37956408) (← links)
- Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus (Q37961847) (← links)
- GLP-1 based therapies: differential effects on fasting and postprandial glucose (Q37974712) (← links)
- The effect of glucagon-like peptide 1 on cardiovascular risk (Q37980019) (← links)
- Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents (Q37992255) (← links)
- Liraglutide: from clinical trials to clinical practice (Q37992256) (← links)
- Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes (Q37995760) (← links)
- Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? (Q38005223) (← links)
- Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough (Q38008004) (← links)
- A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes (Q38020941) (← links)
- Treatment evaluation of liraglutide in type 2 diabetes (Q38035022) (← links)
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (Q38040314) (← links)
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. (Q38055195) (← links)
- Advances in pharmacologic therapies for type 2 diabetes (Q38072616) (← links)